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Fatal ventricular arrhythmias and heart failure are the common modes of death in patients
with cardiovascular diseases. Intracardiac defibrillator (ICD) implantation reduces
arrhythmic mortality to a significant extent in the high risk patient. However, there con-
tinues to be a need for effective drug therapy to reduce the arrhythmic and overall mor-
tality in patients with or without an ICD. Although anti-arrhythmic drugs (AAD) appear
inferior to ICD, the role of beta-blockers and to an extent amiodarone along with non AAD
like angiotensin converting enzyme inhibitors (ACE-I), mineralocorticoid blockers (MRB)
and HMG-CoA reductase inhibitors (statins) need to be emphasized. There have been many
drug trials and meta-analysis to this effect and we review the role of drugs especially in
their ability to reduce arrhythmic mortality and sudden cardiac death (SCD). The focus is
on post myocardial infarction (MI) and heart failure patients with a brief overview of role of
drugs in channelopathies.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Last five decades have shown remarkable improvement in
the cardiovascular mortality with advances in drug and non-
drug therapy in heart diseases. In drug therapy, from aspirin
to thrombolytics, beta-blockers to angiotensin receptor an-
tagonists to statins, all have contributed in improving sur-
vival in patients with coronary artery disease, hypertension
and left ventricular dysfunction. Although from a practical
stand-point reduction in all-cause mortality is what is
desired, from a scientific perspective the reasons driving
mortality reduction is important. The current review is spe-
cifically aimed to determine the influence of drugs on
reduction of arrhythmic mortality in various subsets of car-
diac diseases.entre, Flat No. 10, Nanda
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Post MI, there is a mortality of 5e15% in the first year.1,2 With
advances in pharmacotherapy and interventional treatment
there has been a steady decline in mortality.
Beta-blockers e the BHAT3 trial was one of the early study
that established the role of beta-blockers in reducing total and
arrhythmicmortality, in patients afterMI. Despite subsequent
more evidences to suggest the benefit of beta-blocker post MI,
it continued to be under-utilized. The Cooperative Cardio-
vascular Project revealed that only 34% patients post MI
received beta-blockers and there was a 40% reduction in
mortality when they were prescribed at discharge.4 A meta-
analysis by Freemantle5 showed an overall 23% mortality
reduction with long-term trials using beta-blockers post MIdeep, 209-d, Dr. Ambedkar Road, Matunga (East), Mumbai 400019,
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carvedilol in post MI patients with LVEF < 0.40, established
mortality benefit in patients with LV dysfunction. A long-term
analysis of CAPRICORN patients showed a reduction of 63% in
sustained ventricular tachyarrhythmias.7 Importantly, benefit
with beta-blockers persisted even in patients taking ACE-I.
Class I AADe the CAST I and II study compared Class I anti-
arrhythmic drugs (encainide, flecainide or morcizine) with
placebo in the post MI patients with premature ventricular
complexes (PVC).8,9 There was a higher arrhythmic and non-
arrhythmic mortality in the AAD arm despite suppression of
PVCs. Mexiletine and disopyramide also met similar fate. In
fact, a meta-analysis of 61 RCTs in over 23,000 patients, with
Class I AAD showed an increased overall mortality.10
Class III AAD e Julian et al studied d,l-sotalol, post MI (5e15
days), and showed a lower mortality at 1 year follow-up, how-
ever this was not statistically significant.11 The SWORD study
on d-sotalol in immediate post MI (6e42 days) and remote MI
(>42 days) with LVEF < 0.40, was terminated prematurely as
there was a higher arrhythmic and all-cause mortality with
sotalol.12 D-sotalol has virtually no beta-blocking property and
was chosen in SWORD trial to prevent heart failure in LV
dysfunction patients. Absence of beta-blocking effect in fact
became counter-productive and increased mortality. Interest
in d,l-sotalol has been revived in the ICD era as it lowers the
defibrillation threshold and importantly reduces the frequency
of ICD shocks and lowers mortality.13
The BASIS trial, was a small study (312 patients) on amio-
darone in post MI patients with frequent multifocal or repet-
itive PVC. There was a significant reduction in total mortality
and arrhythmic events with amiodarone.14 The Polish
study, though demonstrated a borderline reduction in cardiac
mortality and ventricular arrhythmias, it did not improve
overall survival at one year follow-up with amiodarone in the
post MI patients.15 The CAMIAT randomized post MI patients
with greater than 10 PVC/h, comparing amiodarone versus
placebo. Amiodarone showed a significant reduction in
arrhythmic deaths (4.5% versus 6.9%, p ¼ 0.016); however
there was no significant reduction in total mortality.16 The
EMIAT study, in post MI patient with LVEF < 0.40, showed a
35% relative risk reduction in arrhythmic deaths with no
reduction in total mortality.17 Thus, amiodarone does reduce
arrhythmic but not overall mortality in the post MI primary
prevention trials. A meta-analysis on amiodarone including
15 trials and 8522 patients, showed a significant 29% reduction
of SCD and 18% reduction of cardiovascularmortality.18 A sub-
group analysis of the post MI patients in this meta-analysis
showed a relative risk reduction of 34% in arrhythmic deaths
and 12% reduction in all-cause deaths. However, amiodarone
trials have demonstrated more non-cardiac deaths and non-
cardiac side effects in the intermediate term follow-up.
Thus, in the post MI patients beta-blockers reduce arrhythmic
and all-cause mortality and should be used in everyone without an
absolute contra-indication. Amiodarone reduces arrhythmic but not
overall mortality and is known to have non-cardiac side effects and
hence is not recommended as a primary prophylaxis drug but may be
considered when necessary, especially when ICD implantation is not
feasible. Sotalol may be considered in patients with recurrent ICD
shocks.ACE inhibitors e are a part of the standard treatment
regimen in post MI patients. The TRACE and AIRE trials
evaluated ACE-I in the post MI population with LV dysfunc-
tion.19,20 There was a 24% and 30% reduction in arrhythmic
mortality in the TRACE and AIRE studies respectively. Both
these trials showed a significant reduction in totalmortality. A
meta-analysis of ACE inhibitors in the post MI period, from 15
trials showed a decrease in SCD, with a 20% relative risk
reduction for SCD (an odds ratio of 0.80, 95% CI 0.70e0.92).21
Direct anti-arrhythmic effect of ACE inhibitors is speculated
but not well understood. It is likely the indirect effects of
preventing LV remodeling, improvement in LV function and
thus preventing fatal ventricular arrhythmias.
In the high risk population for cardiovascular mortality
(vascular disease or diabetes with a cardiac risk factor of hy-
pertension, raised serum lipids etc.), the HOPE study showed a
37% reduction in cardiac arrests and 26% reduction in car-
diovascular mortality.22
ACE-I should therefore be prescribed to all patients post MI and
those with high risk for coronary risk factors to prevent arrhythmic
and overall mortality.
Statinsereduce burden of CAD, MI and cardiovascular
mortality in subjects with known ischemic heart disease/
coronary risk factors. There was a suggestion of non-
significant reduction in fatal arrhythmic outcomes with
statins. Retrospective analysis of AVID sub-group showed a
40% reduction in arrhythmic death or appropriate ICD shock
and similar results were seen in MADIT-II with 28% reduc-
tion in arrhythmic outcomes.23,24 Further, a meta-analysis of
10 RCTs of 22,275 patients on statin therapy, showed a
reduction in SCD from 3.8% to 3%, a 19% risk reduction.25
Retrospective analysis in the SCD-HeFT trial revealed the
mortality reduction with statins was similar in the ischemic
and non-ischemic cardiomyopathy patients. The retrospec-
tive sub-analysis with statin use was overall favorable in
arrhythmic death reduction. However prospective trials like
CORONA26 and GISSI-HF with rosuvastatin failed to show
any benefit. This discrepancy is likely because of the type
and dose of statin studied and severity of heart disease. Beri
et al reviewed 42 clinical trials in the MEDLINE database
addressing the issue of arrhythmic death reduction with
statins.27 They concluded that the reduction in VT/VF and
sudden death was restricted to patients with coronary artery
disease or ischemic cardiomyopathy. No benefit of
arrhythmic death was seen in the non-ischemic cardiomy-
opathy group. They surmised that an anti-ischemic rather
than a primary anti-arrhythmic effect is the likely cause of
SCD reduction with statins.
Statins are strongly recommended for primary and secondary
prevention of CAD. It is not certain whether statins improve
arrhythmic mortality, however they seem to be useful in patients
with ICD to reduce shocks for VT/VF.
Mineralocorticoid receptor blockade e helps to achieve the
final neurohumoral blockade of the renin-angiotensin-
aldosterone pathway by blocking the synthesis of aldoste-
rone. Aldosterone blockade decreases sympathetic activa-
tion, prevents parasympathetic inhibition and avoids
myocardial fibrosis. EPHESUS28 trial (6642 patients), study
of eplerenone in the post MI patients with LVEF < 0.40
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follow-up.28
Eplerenone should be considered in patients with recent MI and
LV dysfunction, however, monitoring renal function and preventing
hyperkalemia should be appropriately addressed.
Ranolazine e the TIMI 36 MERLIN29 study on ranolazine in
the acute coronary syndrome patients did not show benefit in
cardiovascular death, MI or recurrent ischemia. However
there was 37% reduction in VTs lasting 8 or more complexes.
Although there is a potentially perceived benefit with ranolazine in
arrhythmia reduction, it is not conclusively proven to affect the hard
end-point of arrhythmic and overall mortality.3. Non-ischemic dilated cardiomyopathy
There is scanty data in this subset as most studies in heart
failure population have included LV dysfunction of combined,
ischemic and non-ischemic etiology. Beta-blockers and ACE-I
have shown to improve outcomes in all patients with LV
dysfunction and are reviewed later in the heart failure section.
Only the GESICA study, which had significant proportion of
non-ischemic cardiomyopathy showed a 27%, non-significant
reduction in arrhythmic deaths with amiodarone as
compared to placebo (12.3% and 14.2% respectively).30
Although the CHF-STAT study overall did not show any dif-
ference in outcomes with amiodarone, a sub-set analysis of
the non-ischemic group showed a trend towards reduction in
overall mortality.31
The DEFINITE and MADIT-CRT trials sub-analysis of the
non-ischemic cardiomyopathy sub-group, reveal a significant
(>70%) relative risk reduction in the risk of VT/VF or death in
patients with non-ischemic cardiomyopathy, on statin drug
therapy.
Beta-blockers and ACE-I or ARBs should be prescribed to all pa-
tients with non-ischemic dilated cardiomyopathy. Amiodarone is of
value in secondary prevention of arrhythmic events. Amiodarone
and statins may be considered in patients with recurrent ICD shocks
to reduce the frequency of shocks.4. Heart failure
Over the years the incidence and prevalence of the heart
failure population is on the rise. Drug therapy has certainly
contributed to improved survival and outcomes in this high
risk group. The risk of arrhythmic death is high in the heart
failure patients, averaging 5e15% per year, based on the New
York Heart Association (NYHA) class, etiology of heart failure
and the ejection fraction.32 The proportion of patients dying
suddenly is highest in the less severe heart failure group i.e.
NYHA II or III.
Beta-blockerseimproving the symptoms status and survival
in heart failure was the turning point in management of
these patients. The concept of up-regulation of beta-blockers
and subsequently neurohumoral blockade was confirmed in
clinical trials. The US Carvedilol trial was the first to show a
65% reduction in mortality with carvedilol in heart failure
patients with LVEF < 0.35.33 Arrhythmic death reduced from
3.8% to 1.7%. These impressive results led to the prematuretermination of the trial favoring the use of carvedilol. The
CIBIS-II trial with bisoprolol showed a marked reduction in
arrhythmic mortality from 6.3% to 3.6%, a robust 44% relative
risk reduction. This trial too was prematurely terminated
because of a significant 34% reduction of all-cause mortal-
ity.34 The MERIT-HF trial with sustained release metoprolol
showed a significant, 41% relative risk reduction of
arrhythmic mortality.35 The COPERNICUS trial with carvedilol
in severe heart failure patients showed a significant reduc-
tion in SCD (6.1% with placebo and 3.9% with carvedilol) and
a 35% reduction in all-cause mortality.36 A recent meta-
analysis on beta-blockers of 30 RCTs including 24,779 pa-
tients, for prevention of SCD in heart failure population was
studied by Al-Gobari et al. There was a significant 31%
reduction of SCD risk; the 1 year absolute risk of SCD was
5.5% with beta-blockers and 8.1% with placebo in heart fail-
ure patients.37
Of all anti-arrhythmic drugs, only beta-blockers have convinc-
ingly shown reduction in arrhythmic and all-cause mortality.
Important caveats from trial data are the benefit of beta-blockers is
dose dependant, in addition to the ACE-I and ARBs and should be
continued during hospitalization for heart failure. In the era of ICD,
beta-blockers are known to decrease the frequency of ICD shocks,
increase the time to first shock in secondary prevention of SCD and
lower mortality. Furthermore higher dose of beta-blockers also
improve the success of anti-tachycardia pacing.
ACE-I or ARBs e ACE inhibitors in heart failure patients
have shown not only reduction in all-cause and cardiovas-
cular mortality but also a trend in reduction of arrhythmic
deaths. The V-HEFT II trial compared enalapril to hydralazine
and isosorbide dinitrate in patients with chronic congestive
heart failure. There was a 28% reduction in mortality at 2
years, primarily due to a reduction in SCD.38 The SOLVD-Pre-
vention trial with enalapril, showed amodest, non-significant
mortality reduction but no impact on SCD. A meta-analysis of
7105 patients with heart failure on ACE-I, showed a non-
significant reduction of SCD from 5.6% to 4.7%.39,40
Angiotensin receptor blockers have been compared or
added to ACE-I, in the, ELITE I and II, Val-HeFT and CHARM
trials.41e44 Only the smaller ELITE I study demonstrated a 36%
reduction in SCD, which was not reproduced in the larger
ELITE II or any other ARB trial. Overall the ARBs did not show
improvement in outcomes as compared to ACE inhibitors in
heart failure patients.
ACE-I and ARBs exert a multifactorial benefit in patients
with dilated cardiomyopathy. With a decrease in catechol-
amines and calcium overload, ACE-I suppress endogenous
endothelin secretion, reduce sudden vasoconstriction, lessen
ventricular dysfunction and thus reduce arrhythmias. ACE
inhibitors increase ATP and coronary blood flow and poten-
tially decrease the risk of VF. There appears to be a genetic
basis for the benefits of ACE inhibitors. Patients with an ACE
DD genotype and angiotensin II type 1C allele have a higher
risk for ventricular arrhythmias.
ACE-I are pivotal in improving outcomes in patients with LV
dysfunction. The survival benefit is predominantly due to the
improvement in heart failure status and there is a non-significant
trend towards reduction in arrhythmic mortality. ARBs are not su-
perior to ACE-I and are used when patients are intolerant to the
latter.
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ronolactone in class IIIeIV CHF patients and LVEF < 35%,
showed a significant 36% reduction in heart failure and 29%
reduction in SCD.45 Similar to eplerenone use, care should be
taken to avoid hyperkalemia with the use of spironolactone.
Amiodarone vis a vis ICDeAmiodarone has been evaluated in
comparison to ICD in patients presenting with ventricular
arrhythmias or resuscitated SCD and in patients at high risk of
VT/VF/SCD, as primary prophylaxis. The AVID trial, compared
anti-arrhythmic (predominantly amiodarone) drugs to ICD in
patients presenting with VT/VF or resuscitated SCD.46 The
overall survival was significantly more with ICD at 3 years.
The benefit of ICD was not significant in a sub-group of
patients with EF > 35%. The CIDS study also showed a non-
significant trend towards reduced arrhythmic death and all-
cause mortality with ICD (p ¼ 0.09) as compared to amiodar-
one.47 In the CASH study, ICD showed a 23%, non-significant
reduction of all-cause mortality versus amiodarone/meto-
prolol.48 Both these trials suggest that amiodarone or meto-
prolol and may be a combination of both these anti-
arrhythmics might be a viable alternative for patients in
whom ICD cannot be implanted. However a meta-analysis of
these secondary prevention trials clearly identifies a 28%
relative reduction in death primarily because of a 50% reduc-
tion in arrhythmic mortality with ICD.49 Amongst the primary
prevention trials, in the non-ischemic dilated cardiomyopathy
patients e the CAT and AMIOVIRT (smaller studies) did not
show benefit with ICD as compared to amiodarone.50,51
However SCD-HeFT, a larger trial in heart failure patients
with near equal representation of ischemic and non-ischemic
cardiomyopathy patients showed amiodarone was no better
than placebo and established the superiority of ICD in heart
failure patients.52
The OPTIC study suggests the usefulness of amiodarone
and beta-blockers in patients with ICD implantation to reduce
the ICD shocks.53 Amiodarone, though a class III anti-
arrhythmic drug in the Vaughan-Williams classification, ex-
erts properties of all other class as well and therefore less
prone to proarrhythmias. However the non-cardiovascular
side effects of amiodarone e 2e5 fold increase in lung and
thyroid toxicity are the major limitations in its long-term use.
A prospective registry database of patients not implantedwith
ICD because of cost constraintsmight help to further establish
the extent with which anti-arrhythmic drugs like beta-
blockers and amiodarone alone or in combination, help to
reduce overall and arrhythmic deaths.
ICD is the most effective therapy, as both primary and secondary
prevention of arrhythmic deaths in the heart failure population. Its
evidence is much stronger in the ischemic cardiomyopathy patients
but also benefits patients with non-ischemic cardiomyopathy.
Amiodarone may be considered for secondary prevention of VT/VF/
SCD in those whom ICD cannot be implanted. Amiodarone along
with beta-blockers are known to reduce the incidence of ICD shocks.5. Fish oils
The interest in n-3 poly-unsaturated fatty acids (omega-3 fats,
fish oils) to prevent cardiovascular disease dates back to 1976.
The GISSI-Prevenzione trial showed a significant all-cause andcardiovascular deaths primarily driven by reduction in SCD.54
Hence an interest generated in fish oils to reduce arrhythmic
deaths. The JELIS study in over 18,645 patients showed a 19%
relative reduction in major coronary events but sudden car-
diac death and coronary deaths did not differ between the
eicosapentaenoic plus statins group versus statins only on a
long-term follow up.55 A systematic review andmeta-analysis
of 20 studies including 68,680 patients clarifies that omega-3
supplements do not lower all-cause mortality, cardiac or
sudden death, in patients randomized to fish oil or placebo
over more than one year follow-up in primary or secondary
prevention of cardiovascular diseases or in addition to ICD
implantation.56 The varying event rates, baseline risk esti-
mates, co-interventions and drug dosing along with compli-
ance issues were the important reasons for conflicting
outcomes in the earlier RCTs and therefore a meta-analysis
seems more reliable to predict real life outcomes.
Omega-3 fatty acids are not to be routinely prescribed to improve
cardiovascular outcomes and needs to be tailored to individual pa-
tient profile.6. Channelopathies
Various ion channel gene defects result in VT/VF and SCD in
the young. ICD is the definitive therapy for prevention of
arrhythmic deaths in these patients. However drug therapy in
isolation or in combination of device therapy is required in
many patients. Cost, young age, recurrent shocks for VT/VF
precipitating arrhythmic storm are some of the reasons
wherein drug therapy continues to play an important role
despite the availability and implantation of ICD in these
patients.
Long QT syndromeecongenital long QT (LQT) syndrome re-
sults from gene defect in the ion channels responsible for
repolarization.Most often decreased outward Kþ current IKS or
IKR or gain of function of the Na
þþ current results in pro-
pensity to polymorphic VT and SCD. Almost 12 different ge-
netic mutations have been identified.
Beta-blockers have a significant positive impact in
reducing the incidence of syncope and sudden cardiac
death.57 A high dose of beta-blocker i.e. 2e4 mg/kg/day of
propranolol has been successful to an extent in reducing
mortality. In patients persisting to have syncope despite beta-
blockers, pacemaker implantation, left cardiac sympathetic
denervation and ICD implantation help further improve out-
comes. Based on the genotype, experimental and small
studies have suggested the role of Kþ channel openers like
nicorandil, Naþþ channel blocker like flecainide or QT short-
ening drug like mexiletine to have a role in certain subset of
LQT syndrome patients. However there has been no trial data
evaluating these drugs, because the number of such patients
is too small to be tested in clinical trials.
Brugada syndrome e is a genetic, hereditary disorder,
manifesting as characteristic ST elevation in the right pre-
cordial leads predisposing to VT/VF and SCD. Most often
mutation in SCN5A gene resulting in loss of function of INa
causes heterogeneity of repolarization, predominantly in the
right ventricular outflow region and resulting in reentrant
arrhythmias. There is clear evidence for ICD implantation in
Table 1 e Drugs that impact arrhythmic, cardiovascular and all-cause mortality.
Clinical condition Arrhythmic mortality
reduction
Cardiovascular mortality
reduction
All-cause mortality
reduction
Beta-blockers Post MI, CHF þþ þþþ þþþ
Amiodarone Post MI þ Neutral Neutral
ACE-I/ARB Post MI, CHF þ þþþ þþþ
MRB CHF, post MI þ þþ þþ
Statins CAD þ þþ þþ
Fish oil CAD, CHF e e e
þ: Statistically non-significant reduction.
þþ/þþþ: Statistically significant reduction.
e: No benefit.
ACE-I: Angiotensin converter enzyme inhibitor.
ARB: Angiotensin receptor blocker.
MRB: Mineralocorticoid blocker.
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and or VT/VF in such patients. Quinidine suppresses Ito cur-
rent and can reduce the incidence of arrhythmias.58 However,
benefit with quinidine is proposed based on theoretical and
experimental considerations and lacks trial data scrutiny.
Catecholaminergic polymorphic VT/VFeresults in exercise
induced syncope and SCD. The mutation is in the ryanodine
receptor (RyR2), is autosomal dominant. The resting ECG is
normal and therefore making it difficult to diagnose. Charac-
teristic ECG changes may be seen during exercise like bi-
directional VT or simply high grade ventricular ectopy and
polymorphic VT. As in LQT syndrome patients, beta-blockers
are recommended in symptomatic patients and asymptom-
atic gene carriers. There is no clinical trial data available. Left
cardiac sympathetic denervation is suggested in patients not
responsive to beta-blockers and ICD appears to be the most
effective life-saving measure.59
Short QT syndromeeis a relatively recent addition to the list
of channelopathies with a smaller number of patients with
established diagnosis. The genetic defect responsible is the Kþ
channel with gain in function resulting in resting ECG
showing a short QT (240e320 ms) and resulting in atrial
fibrillation and VT/VF. ICD implantation may be the primary
therapy, however quinidine may be useful as adjunctive
therapy based on some clinical and experimental data.607. Conclusion
Appropriate drug therapy reduces arrhythmic and often all-
cause mortality in post MI and heart failure patients (Table 1).
Amongst the AADs only beta-blockers convincingly improve
survival and prevent SCD in post MI and CHF patients. Amio-
darone in the post MI group reduces arrhythmic mortality but
not overall mortality. It is neutral for mortality and therefore a
safe AAD to consider when required. ICD remains the most
effective strategy in reducing arrhythmic deaths. ICD is expen-
siveand insomepatientsamiodarone isa reasonablealternative
(not as a replacement for ICD) for secondary prophylaxis and
also in conjunction with an ICD to reduce the frequency of
shocks.However it isnotdesirable touseamiodaroneasprimary
prophylaxis with no proven benefit and serious long-term side
effects. In theeraof ICD itwouldbeprudent to remember thatallhigh risk patientsmay ormay not have an ICD but every patient
with cardiovascular diseases should be on optimal drug therapy
to improve survival outcomes.
The non AADs like ACE-I have shown reduction in
arrhythmic and overall mortality by favorable alteration of
remodeling and improvement in LV function. The ARBs have
no advantage over the ACE-I but can be substituted in patients
not tolerant to ACE-I. Aldosterone antagonists have shown a
reduction in arrhythmic and overall mortality in heart failure
and post MI patients. Statins show a favorable reduction in
arrhythmic mortality in patients with CAD. Ranolazine, fish
oils are more speculative in reduction of cardiovascular mor-
tality and not corroborated by large RCTs or meta-analysis.
The role of AAD in various channelopathies as primary and
secondary prophylaxis in prevention of SCD has not been
evaluated in RCTs and this is not likely to happen knowing the
limited population pool in this subset. Hence ICD remains the
therapyof choice in survivorsof SCDand in thehigh riskgroup.
However the young age of patients continue to remain a chal-
lenge for ICD implantationand therefore drug therapy remains
a practical, first step solution for some of these patients.Conflicts of interest
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